Empagliflozin and Eplerenone in Heart Failure with Preserved Ejection Fraction
Yes, both empagliflozin and eplerenone are appropriate for your clinical scenario of preserved ejection fraction with mild left ventricular chamber enlargement and grade 1 diastolic dysfunction, even without systolic dysfunction. These medications are now indicated for heart failure with preserved ejection fraction (HFpEF), not just reduced ejection fraction.
Empagliflozin (Jardiance) in HFpEF
The evidence base has fundamentally shifted regarding SGLT2 inhibitors in preserved ejection fraction. The 2025 Canadian guidelines explicitly recommend empagliflozin for heart failure with nonreduced ejection fraction (LVEF >40%), starting at 10 mg daily 1. This represents a major paradigm change from older thinking that these drugs only worked in reduced ejection fraction.
Key Supporting Evidence
The FDA label for Jardiance now includes HFpEF as an indication based on the EMPEROR-PRESERVED trial, which enrolled 5,988 patients with LVEF >40% 2. Empagliflozin reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 21% (HR 0.79,95% CI 0.69-0.90, p=0.0003), primarily through reducing hospitalizations 2.
Critically, this benefit extended across the entire spectrum of preserved ejection fraction:
- The drug worked in patients with LVEF 50-64% 3, 4
- Benefits were consistent regardless of diabetes status 5
- The effect was maintained even in patients with LVEF as high as 65%, though somewhat attenuated above that threshold 4
Mechanism in Diastolic Dysfunction
Your specific concern about diastolic dysfunction is directly addressed by mechanistic research. Empagliflozin improves diastolic function through multiple pathways 6:
- Reduces interstitial myocardial fibrosis
- Improves cardiomyocyte relaxation by enhancing titin phosphorylation
- Activates the nitric oxide-cGMP-PKG signaling pathway
- Enhances autophagy via the AMPK/mTORC1 pathway 7
These mechanisms directly target the pathophysiology of diastolic dysfunction, not just systolic function.
Eplerenone in Your Clinical Context
The evidence for eplerenone in preserved ejection fraction is more nuanced but still supportive. The 2025 Canadian guidelines recommend mineralocorticoid receptor antagonists (including eplerenone 25-50 mg daily) for HFnrEF 1.
Important Caveats for Eplerenone
The FDA label for eplerenone is based primarily on the EPHESUS trial, which studied patients post-myocardial infarction with LVEF ≤40% 8. However, the guideline recommendation extends to preserved ejection fraction based on:
- Mechanistic benefits in reducing fibrosis and cardiac remodeling
- The 2024 European Heart Journal systematic review of HFpEF guidelines supporting MRA use 9
- Extrapolation from the broader heart failure literature
Key monitoring requirement: You must closely monitor potassium and renal function, as eplerenone increases hyperkalemia risk, especially when combined with ACE inhibitors or ARBs 8. Avoid if baseline potassium >5.0 mEq/L or creatinine >2.5 mg/dL 8.
Clinical Algorithm for Your Situation
For mild LV chamber enlargement with grade 1 diastolic dysfunction and preserved EF:
Start empagliflozin 10 mg daily first - This has the strongest evidence in your exact clinical scenario 1, 2
- No titration needed; 10 mg is the therapeutic dose
- Monitor for genital infections, volume depletion
- Benefits appear within weeks
Add eplerenone 25 mg daily if:
- You have hypertension requiring additional control
- There are signs of neurohormonal activation (elevated natriuretic peptides)
- Potassium <5.0 mEq/L and creatinine <2.5 mg/dL
- Titrate to 50 mg daily after 4 weeks if tolerated 1
Monitor closely:
- Potassium and creatinine at 1 week, then monthly for first 3 months
- Blood pressure (both drugs lower BP)
- Symptoms of volume depletion
Common Pitfalls to Avoid
- Don't wait for symptoms to worsen: The evidence shows benefit even in early/mild disease 1, 2
- Don't assume these are "diabetes drugs": Benefits are independent of diabetes status 5
- Don't combine eplerenone with potassium-sparing diuretics or potassium supplements without very close monitoring
- Don't use empagliflozin if eGFR <20 mL/min/1.73m² (though it works well in chronic kidney disease above this threshold) 2
The 2024 European systematic review emphasizes that SGLT2 inhibitors represent the first disease-modifying therapy for HFpEF 9, fundamentally changing how we approach preserved ejection fraction. Your clinical scenario—mild diastolic dysfunction with preserved EF—is precisely the population that benefits from these medications.